Patients at increased risk
Risk factors for severe drug-induced hepatotoxicity with lenalidomide may include pre-existing viral liver disease, elevated baseline liver enzymes, and antibiotic treatment.
Monitoring of liver function is recommended, particularly when there is a history of, or concurrent, viral liver infection or when lenalidomide is combined with other medications known to be associated with liver dysfunction (eg, paracetamol).
As lenalidomide is substantially excreted by the kidneys, dose adjustment is required in patients with renal impairment.
Further information: Celgene Ltd